Logo

Adalimumab biosimilar wins NMPA approval

Share this
Adalimumab biosimilar wins NMPA approval

Adalimumab biosimilar wins NMPA approval

Shanghai Junshi Biosciences Co. Ltd. and Mabwell Bioscience Co. Ltd. announced that the jointly developed adalimumab biosimilar injection (Junmaikang ®) was officially approved by the Chinese National Medical Products Administration (NMPA) for marketing authorization (drug approval number: Sinopharm S20220008). Junmaikang® is used for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, and received major scientific and technological support from the National 12th Five-Year Plan for Major New Drug Creation Science and Technology.

Adalimumab, sold under the brand name Humira® among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis.

Share this article on WhatsApp, LinkedIn and Twitter



Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions